Notify Therapeutics

Notify Therapeutics develops a non-hormonal fertility treatment targeting the initial hormone-independent phase of ovarian follicle development. The therapy is designed for women who are unresponsive or low responders to standard hormone treatments, including those with low ovarian reserves. The company has demonstrated proof-of-concept in rodent models and ex-vivo patient samples, aiming to generate quality eggs without the risks associated with multiple pregnancies.